Gilead Sciences, Inc. GILD
Composite 49/100; the shares have moved about 26% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 30/100 — a moderate mark against it.
Growth ranks 69/100 — a moderate point in its favour. Income ranks 62/100 — a slight point in its favour. Momentum ranks 61/100 — a slight point in its favour.
Valuation ranks 30/100 — a moderate mark against it. Balance-sheet strength ranks 40/100 — a slight mark against it. Quality ranks 48/100 — a slight mark against it.
What the company does Gilead Sciences discovers, develops, and commercializes medicines for unmet medical needs, including HIV treatments (e.g., Biktarvy, Descovy), hepatitis therapies (e.g., Epclusa, Vemlidy), and CAR T-cell therapies (e.g., Yescarta, Tecartus). The company also focuses on immunotherapies for cancer and incurable diseases, with collaborations spanning multiple biopharma partners.
Key financials Gilead reports gross margins of 79.6% but net margins of -10.6%, reflecting high R&D and restructuring costs. Revenue grew 2.4% YoY, while EPS surged 1672.9% due to one-time items. Debt/Equity stands at 2.23, with a current ratio of 1.26 and FCF yield of 5.3%. Dividend yield is 2.2% with a 43.4% payout ratio.
Stock health The stock shows strong momentum over 3 months (13.85%) but is down -2.18% over 6 months. RSI(14) is elevated at 74.10, signaling potential overbought conditions. Sideravia scores the stock average quality (48.1/100), with growth (70.1) offset by weak valuation (29.9) and strength (39.3).
Price vs fair value Gilead trades at a **discount of 6.60%** to the analyst mean target of 157.41. - Recent court ruling removes a litigation overhang (TheStreet). - Expanding HIV portfolio cited as a growth catalyst (Zacks). - Turnaround narrative gaining Wall Street attention (Motley Fool). - Biotech sector momentum driving investor interest (Barrons.com).
Looking forward Forward P/E is 15.22, below historical averages, but high EV/EBITDA (104.30) reflects premium valuation metrics. Growth initiatives in HIV and oncology, alongside pipeline advancements, may support long-term value. Monitor execution on pipeline catalysts and margin recovery.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.